Trimethoprim-Sulfamethoxazole and Acute Respiratory Failure in Adolescents and Young Adults
These findings suggest that the 30-day risk of a hospital visit with acute respiratory failure was higher among those receiving TMP-SMX compared with those receiving amoxicillin or cephalosporins. These findings supported the FDA warning, and if replicated, the risks should be carefully weighed against the benefits of TMP-SMX use. Regulatory agencies could reinforce the FDA warning, and product monographs and prescribing guidelines should be updated and revised accordingly.
Authors
- Eric McArthur (ORCID: https://orcid.org/0009-0000-6944-6471)
- Facundo García‐Bournissen (ORCID: https://orcid.org/0000-0002-8732-247X)
- Flory Tsobo Muanda (ORCID: https://orcid.org/0000-0003-4682-6564)
- Michael Rieder (ORCID: https://orcid.org/0000-0003-3079-2873)
- Fatemeh Ahmadi (ORCID: https://orcid.org/0000-0002-9562-1760)
Institutions
- Western University (CA)
- London Health Sciences Centre (CA)
- Institute for Clinical Evaluative Sciences (CA)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.45251
- Citations
- 2
- Primary Topic
- Pneumocystis jirovecii pneumonia detection and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Lawson Health Research Institute
- Academic Medical Organization of Southwestern Ontario
- Canadian Institutes of Health Research
- Schulich School of Medicine and Dentistry